Dir., Interim President and Chief Executive Officer at Impax Laboratories, Inc.
J. Kevin Buchi served as our Interim President and Chief Executive Officer from December 19, 2016 until March 27, 2017. From August 2013 to December 2016, Mr. Buchi served as President and Chief Executive Officer and a member of the board of directors of TetraLogic Pharmaceuticals Corporation (formerly NASDAQ: TLOG), a clinical-stage biopharmaceutical company ("TetraLogic Pharmaceuticals"), which assets were subsequently acquired by Medivir AB in December 2016. Prior to his time at TetraLogic Pharmaceuticals, Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a pharmaceut ...
Source: Impax Laboratories, Inc. on 04/05/2017
By accessing BoardEdge, you can view bios, network, connections and references of industry leading executives like J. Kevin Buchi. More specifically, you'll be able to:
Access over 170,000 executive and board member profiles.
Example: J. Kevin Buchi
Interested in updating your biography and work history?
We're working on making it happen.
We'll email you when this feature is available.
Please enter valid email address.
Thank you for your interest.